ONCO

0.0759

4.29% -0.0034

Handel nachbörslich: .08 0.0041 +5.40%

Onconetix Inc (ONCO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$0.0793

Offen:

$0.0732

24-Stunden-Volumen:

2.33M

Relative Volume:

0.21

Marktkapitalisierung:

$1.04M

Einnahmen:

Nettoeinkommen (Verlust:

$-53.12M

KGV:

-0.000698

EPS:

-108.8

Netto-Cashflow:

$-15.86M

1W Leistung:

-29.53%

1M Leistung:

-69.94%

6M Leistung:

-98.31%

1J Leistung:

-98.86%

1-Tages-Spanne:

$0.067

$0.0759

1-Wochen-Bereich:

$0.065

$0.0999

52-Wochen-Spanne:

$0.065

$21.40

Onconetix Inc Stock (ONCO) Company Profile

Firmenname

Onconetix Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (678)

Telefon

513-620-4101

Adresse

201 E. FIFTH STREET, CINCINNATI

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-05-30

Neueste SEC-Einreichungen

ONCO's Discussions on Twitter

Vergleichen Sie ONCO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ONCO Onconetix Inc	0.0759	1.04M	0	-53.12M	-15.86M	-108.80
VRTX Vertex Pharmaceuticals Inc	484.01	125.55B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	67.78B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	36.24B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.99B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.77B	3.81B	-644.79M	-669.77M	-6.24

Onconetix Inc Aktie (ONCO) Neueste Nachrichten

Apr 01, 2025

Onconetix Delays Yearly Report Filing - TipRanks

Apr 01, 2025

Mar 27, 2025

Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews

Mar 27, 2025

Mar 25, 2025

Onconetix claims validation of prostate cancer test Proclarix in Danish cohort - Yahoo Finance

Mar 25, 2025

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewswire

Mar 25, 2025

Mar 24, 2025

Onconetix reveals Proclarix’s clinical performance at EAU congress - Investing.com India

Mar 24, 2025

Onconetix Announces Successful Clinical Validation Of Proclarix For Prostate Cancer In Danish Cohort - Nasdaq

Mar 24, 2025

Onconetix reveals Proclarix’s clinical performance at EAU congress By Investing.com - Investing.com South Africa

Mar 24, 2025

Onconetix Inc. Presents Promising Clinical Data for Proclarix® at 2025 EAU Congress - Nasdaq

Mar 24, 2025

Revolutionary Prostate Cancer Test Cuts Unnecessary Biopsies by 22%, Shows 96% Detection Rate - Stock Titan

Mar 24, 2025

Mar 21, 2025

Onconetix, Inc. to Present Proclarix Study Results at 2025 EAU Congress in Madrid - Nasdaq

Mar 19, 2025

Groundbreaking 800-Patient Study Shows How Onconetix's Proclarix Test Prevents Unnecessary Prostate Biopsies - StockTitan

Mar 19, 2025

ONCO stock plunges to 52-week low, touches $0.12 By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

ONCO stock plunges to 52-week low, touches $0.12 - Investing.com India

Mar 18, 2025

Mar 03, 2025

Onconetix taps industry veteran as executive chairman amid CEO resignation - The Business Journals

Mar 03, 2025

Feb 28, 2025

Onconetix names new executive chairman, appoints board member By Investing.com - Investing.com Australia

Feb 28, 2025

Onconetix names new executive chairman, appoints board member - Investing.com India

Feb 28, 2025

Onconetix Announces Leadership Changes and New Appointments - TipRanks

Feb 28, 2025

Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science Officer -February 28, 2025 at 05:35 pm EST - Marketscreener.com

Feb 28, 2025

Feb 19, 2025

Onconetix secures new financing, appoints auditor, sees executive exit By Investing.com - Investing.com South Africa

Feb 19, 2025

Feb 18, 2025

Onconetix secures new financing, appoints auditor, sees executive exit - Investing.com

Feb 18, 2025

Onconetix Announces Promissory Note Agreement with Keystone - TipRanks

Feb 18, 2025

Feb 05, 2025

Investing in Onconetix Inc (ONCO) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News

Feb 05, 2025

Feb 04, 2025